Syros Pharmaceuticals Inc (NASDAQ:SYRS)‘s stock had its “buy” rating reissued by equities researchers at Piper Jaffray Cos. in a research note issued to investors on Thursday. They presently have a $20.00 price objective on the stock. Piper Jaffray Cos.’s target price indicates a potential upside of 50.94% from the company’s current price.

SYRS has been the topic of several other research reports. Cowen and Company assumed coverage on Syros Pharmaceuticals in a research report on Monday, July 25th. They set an “outperform” rating on the stock. HC Wainwright reissued a “hold” rating and set a $10.00 target price on shares of Syros Pharmaceuticals in a research report on Friday, September 9th. Wedbush assumed coverage on Syros Pharmaceuticals in a research report on Monday, July 25th. They set an “outperform” rating and a $18.00 target price on the stock. Zacks Investment Research lowered Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday. Finally, JMP Securities assumed coverage on Syros Pharmaceuticals in a research report on Monday, July 25th. They set an “outperform” rating and a $22.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $17.50.

Shares of Syros Pharmaceuticals (NASDAQ:SYRS) traded up 0.38% on Thursday, hitting $13.30. The stock had a trading volume of 700 shares. The firm has a 50 day moving average of $11.67 and a 200 day moving average of $12.69. The stock’s market cap is $310.87 million. Syros Pharmaceuticals has a 12 month low of $8.16 and a 12 month high of $21.50.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/syros-pharmaceuticals-inc-syrs-stock-rating-reaffirmed-by-piper-jaffray-cos.html

In other news, Director Robert Nelsen purchased 400,000 shares of the business’s stock in a transaction on Wednesday, July 6th. The shares were bought at an average price of $12.50 per share, with a total value of $5,000,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Redmile Group, Llc purchased 432,746 shares of the business’s stock in a transaction on Wednesday, July 6th. The shares were purchased at an average cost of $12.50 per share, for a total transaction of $5,409,325.00. The disclosure for this purchase can be found here.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Weiss Multi Strategy Advisers LLC purchased a new position in Syros Pharmaceuticals during the second quarter valued at approximately $832,000. Redmile Group LLC purchased a new position in Syros Pharmaceuticals during the second quarter valued at approximately $15,058,000. Aisling Capital LLC purchased a new position in Syros Pharmaceuticals during the second quarter valued at approximately $16,490,000. Deerfield Management Co. purchased a new position in Syros Pharmaceuticals during the second quarter valued at approximately $38,028,000. Finally, Flagship Ventures Fund IV General Partner LLC purchased a new position in Syros Pharmaceuticals during the second quarter valued at approximately $87,241,000.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

5 Day Chart for NASDAQ:SYRS

Receive News & Ratings for Syros Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.